Efficacy of prophylactic use of biologic mesh in ileal conduit: insights from the PUBMIC trial
Editorial Commentary

Efficacy of prophylactic use of biologic mesh in ileal conduit: insights from the PUBMIC trial

Kenji Zennami

Department of Urology, Fujita Health University School of Medicine, Toyoake, Japan

Correspondence to: Kenji Zennami, MD. Department of Urology, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1192, Japan. Email: zenken@fujita-hu.ac.jp.

Comment on: Djaladat H, Ghoreifi A, Tejura T, et al. Prophylactic Use of Biologic Mesh in Ileal Conduit (PUBMIC): A Randomized Clinical Trial. J Urol 2024;211:743-53.


Keywords: Cystectomy; ileal conduit (IC); parastomal hernia (PSH); prophylactic mesh


Submitted Dec 25, 2024. Accepted for publication Mar 31, 2025. Published online May 27, 2025.

doi: 10.21037/tau-2024-764


Parastomal hernia (PSH) has been reported as a common complication after ileal conduit (IC) urinary diversion that impairs quality of life and results in a clinically significant problem for many patients. The rate of PSH has been reported to range from 30% to 65%, including asymptomatic patients (1). Although serious complications such as strangulation and obstruction requiring emergent interventions are rare, PSH repair is considered a challenging surgery with a high recurrence rate (2). In addition, re-surgery itself significantly impairs quality of life and increases other complications besides PSH (3). According to the need for PSH prevention, the randomized controlled trials (RCTs) have been performed on prophylactic mesh use during radical cystectomy with IC, which did not change the radiological PSH rate, while reducing the frequency of clinical hernia (4). Djaladat et al. conducted a RCT including 146 patients who received cystectomy with IC to evaluate the efficacy and safety of the FlexHD prophylactic biological mesh using the sublay intraperitoneal technique (5).

At a median follow-up of 2 years, a significant preventive effect of the prophylactic mesh was not observed in clinical or radiological PSH development. However, careful interpretation is required due to the limitations of the study. Firstly, the follow-up period is only 2 years, which may need more observation to see the long-term preventive effect. Notably, Kaplan-Meier analysis in the present study showed a tendency to reduce long-term PSH similar to the previous study (4). Secondly, this study may have included patients with a relatively low risk of PSH. As their previous study reported independent predictors for radiological PSH, such as female gender, higher body mass index (BMI), diabetes, and chronic obstructive pulmonary disease (6), optimal stratification using those risk factors might reveal the pronounced preventive effect of prophylactic mesh placement. Thirdly, surgical techniques to prevent PSH without using mesh have not been fully elucidated. The stoma construction through the rectus abdominis muscle (7), stoma placement via extraperitoneal route (8), and fixing the stoma to the fascia (9) have been proposed to reduce PSH, although these techniques have not yet been supported by sufficient evidence. Further studies are warranted to establish effective prevention techniques.

Regardless of the limitations mentioned above, we would like to thank the authors for carrying out the RCT of the significant topic. Especially, the confirmation of safe placement of prophylactic biological mesh with short additional operative time and no significant intraoperative complications is a significant finding from this study. Mature data with a longer follow-up period, as well as data from other trials on this topic, are required. Selective use of prophylactic biologic mesh in patients with high-risk of PSH can be considered until mature data are available.


Acknowledgments

None.


Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Translational Andrology and Urology. The article has undergone external peer review.

Peer Review File: Available at https://tau.amegroups.com/article/view/10.21037/tau-2024-764/prf

Funding: None.

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-2024-764/coif). The author has no conflicts of interest to declare.

Ethical Statement: The author is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.


References

  1. Donahue TF, Bochner BH. Parastomal hernias after radical cystectomy and ileal conduit diversion. Investig Clin Urol 2016;57:240-8. [Crossref] [PubMed]
  2. Narang SK, Alam NN, Campain NJ, et al. Parastomal hernia following cystectomy and ileal conduit urinary diversion: a systematic review. Hernia 2017;21:163-75. [Crossref] [PubMed]
  3. Bizzarri FP, Campetella M, Russo P, et al. Risk factors for benign uretero-enteric anastomotic strictures after open radical cystectomy and ileal conduit. Urologia 2025;92:224-30. [Crossref] [PubMed]
  4. Liedberg F, Kollberg P, Allerbo M, et al. Preventing Parastomal Hernia After Ileal Conduit by the Use of a Prophylactic Mesh: A Randomised Study. Eur Urol 2020;78:757-63. [Crossref] [PubMed]
  5. Djaladat H, Ghoreifi A, Tejura T, et al. Prophylactic Use of Biologic Mesh in Ileal Conduit (PUBMIC): A Randomized Clinical Trial. J Urol 2024;211:743-53. [Crossref] [PubMed]
  6. Ghoreifi A, Allgood E, Whang G, et al. Risk factors and natural history of parastomal hernia after radical cystectomy and ileal conduit. BJU Int 2022;130:381-8. [Crossref] [PubMed]
  7. Hardt J, Seyfried S, Weiß C, et al. A pilot single-centre randomized trial assessing the safety and efficacy of lateral pararectus abdominis compared with transrectus abdominis muscle stoma placement in patients with temporary loop ileostomies: the PATRASTOM trial. Colorectal Dis 2016;18:O81-90. [Crossref] [PubMed]
  8. Hardt J, Meerpohl JJ, Metzendorf MI, et al. Lateral pararectal versus transrectal stoma placement for prevention of parastomal herniation. Cochrane Database Syst Rev 2013;CD009487. [Crossref] [PubMed]
  9. Pisters AL, Kamat AM, Wei W, et al. Anterior fascial fixation does not reduce the parastomal hernia rate after radical cystectomy and ileal conduit. Urology 2014;83:1427-32. [Crossref] [PubMed]
Cite this article as: Zennami K. Efficacy of prophylactic use of biologic mesh in ileal conduit: insights from the PUBMIC trial. Transl Androl Urol 2025;14(5):1158-1159. doi: 10.21037/tau-2024-764

Download Citation